Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Mehmet Cem FidanDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0009-0008-8199-4153
Ahmet Emin ÖztürkDepartment of Medical Oncology, University of Health Science, Prof. Dr. Cemil Tascıoglu City Hospital, Istanbul 34360, Türkiye.ORCID 0000-0003-3365-5540
Okan AydınDepartment of Medical Oncology, University of Health Science, Prof. Dr. Cemil Tascıoglu City Hospital, Istanbul 34360, Türkiye.ORCID 0000-0002-9516-992X
Goncagül AkdağDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Türkiye.ORCID 0000-0002-6221-0623
Ezgi TürkoğluDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Türkiye.ORCID 0000-0003-3846-7047
Rumeysa ÇolakDepartment of Medical Oncology, University of Health Science, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul 34147, Türkiye.ORCID 0000-0002-3867-0793
Nargiz MajidovaDivision of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34899, Türkiye.ORCID 0000-0002-2575-5819
Tanju KapağanDepartment of Medical Oncology, Basaksehir Cam and Sakura City Hospıtal, Istanbul 34480, Türkiye.ORCID 0000-0001-9381-1934
Murad GuliyevDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0002-2981-8098
Emir ÇelikDepartment of Medical Oncology, University of Health Science, Prof. Dr. Cemil Tascıoglu City Hospital, Istanbul 34360, Türkiye.
Hatice OdabaşDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Türkiye.ORCID 0000-0002-5757-4705
Mesut YılmazDepartment of Medical Oncology, University of Health Science, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul 34147, Türkiye.ORCID 0000-0003-1466-3887
İbrahim Vedat BayoğluDivision of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34899, Türkiye.
Nilüfer BulutDepartment of Medical Oncology, Basaksehir Cam and Sakura City Hospıtal, Istanbul 34480, Türkiye.
Nebi Serkan DemirciDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Özkan AlanDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0002-6635-2012
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
CDK4/6 inhibitorschemotherapyendocrine resistanceHER2-negative breast cancerHR-positiveliver metastasisoverall survivalpalbociclibprogression-free survivalribociclib
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.